Status:
COMPLETED
A Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at Three Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Tiotropium
Lead Sponsor:
AstraZeneca
Conditions:
Chronic Obstructive Pulmonary Disease
Eligibility:
All Genders
40-80 years
Phase:
PHASE2
Brief Summary
The primary objective is to evaluate the dose-response relationship and efficacy of AZD9668 at 3 dose levels compared with placebo in symptomatic COPD patients by assessing effects on lung function an...
Eligibility Criteria
Inclusion
- Diagnosis of COPD with symptoms over 1 year
- Smokers or ex-smokers
- Males or post-menopausal females between 40 and 80 years old
- Able to use electronic devices
Exclusion
- Past history or current evidence of clinically significant heart disease
- Current diagnosis of asthma
- Patients who require long term oxygen therapy
- Treatment with antibiotics within 4 weeks of study visit 1b
Key Trial Info
Start Date :
July 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2010
Estimated Enrollment :
838 Patients enrolled
Trial Details
Trial ID
NCT00949975
Start Date
July 1 2009
End Date
August 1 2010
Last Update
August 3 2012
Active Locations (105)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Fullerton, California, United States
2
Research Site
Valparaiso, Indiana, United States
3
Research Site
Council Bluffs, Iowa, United States
4
Research Site
Hickory, North Carolina, United States